Macroaxis Story

Macroaxis News
  
By Vlad Skutelnik

October 20, 2019

Today I will concentrate on 8 Giant Impact isntruments to have in your portfolio in November 2019. I will cover United Parcel Service, AbbVie, Texas Instruments Incorporated, Medtronic plc, Novo Nordisk AS, United Technologies Corporation, Nike, and Sanofi
The Top 8 Giant Impact stocks to own in November 2019

This list of potential positions covers Public companies with mega capitalization. An experimental equal-weighted decomposition of large high potential stocks based on Macroaxis scoring framework in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.


United Parcel Service (UPS)

The company has Net Profit Margin of 6.81 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 10.77 % which entails that for every 100 dollars of revenue it generated 0.11 of operating income. The entity currently falls under 'Mega-Cap' category with total capitalization of 105.52 B. United Parcel Service has current Real Value of $108.56 per share. The regular price of the company is $123.02. At this time the company appears to be overvalued. This module measures value of United Parcel Service from inspecting the company fundamentals such as Return On Equity of 114.92 , Shares Outstanding of 700.76 M and Operating Margin of 10.77  as well as reviewing its technical indicators and Probability Of Bankruptcy. In general, we recommend to buy undervalued stocks and to dispose of overvalued stocks since at some point securities prices and their ongoing real values will draw towards each other. United Parcel Service has current Real Value of $108.56 per share. The regular price of the company is $123.02. At this time the company appears to be overvalued. This module measures value of United Parcel Service from inspecting the company fundamentals such as Operating Margin of 10.77 , Return On Equity of 114.92  and Shares Outstanding of 700.76 M as well as reviewing its technical indicators and Probability Of Bankruptcy. In general, we recommend to buy undervalued stocks and to dispose of overvalued stocks since at some point securities prices and their ongoing real values will draw towards each other.

AbbVie (ABBV)

The company has return on total asset (ROA) of 13.45 % which means that it generated profit of $13.45 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 0.32 % meaning that it created $0.32 on every $100 dollars invested by stockholders. The firm currently falls under 'Mega-Cap' category with current market capitalization of 128.15 B.
Total Debt
AbbVie shows prevailing Real Value of $91.05 per share. The current price of the firm is $86.66. At this time the firm appears to be undervalued. This module approximates value of AbbVie from analyzing the firm fundamentals such as Profit Margin of 9.90  and Return On Equity of 0.32  as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point assets prices and their ongoing real values will blend.

Texas Instruments Incorporated (TXN)

The company has Net Profit Margin of 35.16 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 47.06 % which entails that for every 100 dollars of revenue it generated 0.47 of operating income. This firm currently falls under 'Mega-Cap' category with total capitalization of 112.28 B. Texas Instruments has current Real Value of $121.76 per share. The regular price of the company is $118.42. At this time the company appears to be fairly valued. This module measures value of Texas Instruments from inspecting the company fundamentals such as Return On Equity of 53.19 , Operating Margin of 47.06  and Shares Outstanding of 934.77 M as well as reviewing its technical indicators and Probability Of Bankruptcy. In general, we recommend to buy undervalued stocks and to dispose of overvalued stocks since at some point securities prices and their ongoing real values will draw towards each other. Texas Instruments competes with Eltek Ltd, AVX, Flex Ltd, Celestica, Micron Technology, Fabrinet, Benchmark Electronics, Deswell Industries, and Amphenol. Texas Instruments Incorporated designs, manufactures, and sells semiconductors to electronics designers and manufacturers worldwide. The company was founded in 1930 and is headquartered in Dallas, Texas. Texas Instruments operates under Semiconductors classification in USA and is traded on BATS Exchange. It employs 30000 people.

Medtronic plc (MDT)

The company has Net Profit Margin of 0.17 % which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 30.78 % which entails that for every 100 dollars of revenue it generated 0.31 of operating income. The entity currently falls under 'Mega-Cap' category with total capitalization of 148.71 B.
Total Debt

Novo Nordisk AS (NVO)

The company has Return on Asset of 28.26 % which means that on every $100 spent on asset it made $28.26 of profit. This is very large. In the same way, it shows return on shareholders equity (ROE) of 77.1 % implying that it generated $77.1 on every 100 dollars invested. The entity currently falls under 'Mega-Cap' category with total capitalization of 136.07 B. Novo Nordisk AS secures last-minute Real Value of $59.84 per share. The latest price of the firm is $57.64. At this time the firm appears to be fairly valued. This module forecasts value of Novo Nordisk AS from analyzing the firm fundamentals such as Shares Outstanding of 2.36 B, Return On Equity of 77.10  and Profit Margin of 32.46  as well as examining its technical indicators and Probability Of Bankruptcy. In general, we recommend to purchase undervalued stocks and to get rid of overvalued stocks since at some point entities prices and their ongoing real values will merge together. Novo Nordisk competes with Dicerna Pharmaceuticals, Auris Medical, Denali Therapeutics, NantKwest, Equillium, DiaMedica Therapeutics, DYADIC INTERNATIONAL, Dynavax Technologies, and DelMar Pharmaceuticals. Novo Nordisk AS, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. Novo Nordisk operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 42158 people.

United Technologies Corporation (UTX)

The company has Net Profit Margin of 6.72 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 18.98 % which entails that for every 100 dollars of revenue it generated 0.19 of operating income. This firm currently falls under 'Mega-Cap' category with total capitalization of 127.95 B.
Total Debt
United Technologies has current Real Value of $162.34 per share. The regular price of the company is $148.31. At this time the company appears to be undervalued. This module measures value of United Technologies from inspecting the company fundamentals such as Return On Equity of 14.18 , Shares Outstanding of 863.27 M and Operating Margin of 18.98  as well as reviewing its technical indicators and Probability Of Bankruptcy. In general, we recommend to buy undervalued stocks and to dispose of overvalued stocks since at some point securities prices and their ongoing real values will draw towards each other.

Nike (NKE)

The company has Net Profit Margin of 0.1 % which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 14.04 % which entails that for every 100 dollars of revenue it generated 0.14 of operating income. The entity currently falls under 'Mega-Cap' category with total capitalization of 137.4 B. Nike secures last-minute Real Value of $97.89 per share. The latest price of the firm is $91.29. At this time the firm appears to be undervalued. This module forecasts value of Nike from analyzing the firm fundamentals such as Current Valuation of 134.63 B, Profit Margin of 0.10  and Return On Equity of 0.20  as well as examining its technical indicators and Probability Of Bankruptcy. In general, we recommend to purchase undervalued stocks and to get rid of overvalued stocks since at some point entities prices and their ongoing real values will merge together.

Sanofi (SNY)

The company has Return on Asset of 3.6 % which means that on every $100 spent on asset it made $3.6 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 6.47 % implying that it generated $6.47 on every 100 dollars invested. This firm currently falls under 'Mega-Cap' category with total capitalization of 114.83 B.

Current 8 Giant Impact Recommendations

Competition Technical Indicators

Mean
Deviation
Jensen
Alpha
Sortino
Ratio
Treynor
Ratio
Semi
Deviation
Information
Ratio
Expected
Shortfall
Potential
Upside
Value
At Risk
Maximum
Drawdown
 0.69  0.11  0.06  0.47  0.88  0.06 (0.73)  1.73 (1.57)  4.67 
 0.89 (0.05) (0.05) (0.01)  1.50 (0.06) (0.87)  1.76 (1.99)  8.27 
 0.70 (0.06)  0.00 (0.07)  0.00 (0.12)  0.00  1.24 (1.24)  4.03 
 0.88  0.00 (0.02)  0.07  1.08 (0.0206) (0.90)  1.60 (1.86)  4.36 
 1.02 (0.08)  0.00 (0.03)  0.00 (0.08)  0.00  2.07 (2.22)  5.64 
 2.83  0.31  0.00 (2.43)  0.00  0.03  0.00  17.71 (9.10)  43.11 
 0.97  0.06  0.01  0.20  1.17  0.0133 (0.99)  1.79 (2.04)  7.62 
 0.88  0.06  0.03  0.15  1.10  0.0323 (0.91)  1.94 (2.11)  5.88 
 0.98  0.24  0.03 (0.22)  1.29  0.06 (1.73)  3.30 (3.04)  9.82 
 1.06 (0.08)  0.00 (0.03)  0.00 (0.07)  0.00  1.92 (2.38)  6.54 

About Contributor

Vlad Skutelnik
   Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management. View Profile
This story should be regarded as informational only and should not be considered as solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Macroaxis. Please refer to our Terms of Use for any information regarding our disclosure principles.

Did you try this?

Run Price Exposure Probability Now

   

Price Exposure Probability

Analyze equity upside and downside potential for a given time horizon across multiple markets
All  Next Launch Module
See also Stocks Correlation. Please also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Search macroaxis.com